Torsemide

The label describes torsemide for edema associated with heart failure, renal disease or hepatic disease.

It is also described for hypertension, to lower blood pressure. The label notes no controlled trials show risk reduction with torsemide itself.

• Edema with heart failure
• Edema with kidney disease
• Edema with liver disease
• Hypertension

Torsemide acts in the thick ascending loop of Henle in the kidney, where it blocks the Na+/K+/2Cl- carrier.

This increases urinary excretion of sodium and water.

This page covers the US label for torsemide tablets taken by mouth, with the dosing the label gives for adults.

This is label-level information, not personal advice. Indian pack labels may differ, and your prescriber's instruction always comes first.

For edema with heart failure, the label describes an initial dose of 10 or 20 mg once daily, and 20 mg once daily with chronic kidney failure. In cirrhosis, it describes 5 or 10 mg once daily with an aldosterone antagonist or potassium-sparing diuretic.

For hypertension, it describes 5 mg once daily, which may rise to 10 mg after 4 to 6 weeks.

Doses may be raised by roughly doubling. Doses above 200 mg (above 40 mg in cirrhosis) have not been adequately studied.

• Heart failure edema: 10 or 20 mg once daily
• Kidney failure edema: 20 mg once daily
• Cirrhosis edema: 5 or 10 mg once daily
• Hypertension: 5 mg once daily

The label says it is contraindicated in hypersensitivity to torsemide or povidone, in anuria, and in hepatic coma.

Excess diuresis can cause dehydration, low blood pressure and worsening kidney function, especially in salt-depleted patients. Volume status, kidney function and electrolytes need periodic monitoring.

Ototoxicity risk is higher with high doses, severe kidney impairment and low blood protein. Gout may rarely be triggered.

• Not in anuria or hepatic coma
• Not if allergic to torsemide or povidone
• Dehydration and low blood pressure risk
• Electrolytes and kidney function need monitoring
• Hearing effects at high doses

• NSAIDs and salicylates
• Lithium
• Renin-angiotensin inhibitors
• Corticosteroids and cholestyramine
• The label says NSAIDs can reduce the effect of torsemide and raise kidney risk.
• High-dose salicylates can reach toxic levels.
• Lithium toxicity, extra low blood pressure with renin-angiotensin inhibitors, and kidney toxicity with radiocontrast agents are described.
• Corticosteroids raise low-potassium risk, and cholestyramine lowers torsemide exposure.

No match in this label text. Ask your pharmacist about any medicine you take.

The label gives a storage range of 20 to 25 degrees C.

The label also says to keep the container tightly closed.

Follow the storage line on your own pack, and keep medicines out of the reach of children.

We did not find torsemide in the Drugs Rules 1945 Schedule H, H1, X or G rows we checked, so we cannot state its Indian prescription status from our lists. Ask your pharmacist or doctor.

We did not find torsemide on the National List of Essential Medicines 2022 in the list we checked.

The Jan Aushadhi (PMBJP) list we checked has 7 product rows that mention torsemide. We did not capture prices for them.

Jan Aushadhi lists torsemide products including Torsemide Tablets IP 20 mg 20 mg; Torsemide 10mg and Spironolactone 50mg Tablets 10mg; Torsemide Tablets IP 40mg 40mg; Torsemide Tablets IP 5mg 5mg. We have not shown a price for them. Check the pack and the seller for the actual price.